Receptors, Vasopressin

• 

  Subject Areas on Research

  • A multi-ancestry genome-wide study incorporating gene-smoking interactions identifies multiple new loci for pulse pressure and mean arterial pressure. 
  • Age and sex differences in oxytocin and vasopressin V1a receptor binding densities in the rat brain: focus on the social decision-making network. 
  • Allosteric activation of proto-oncogene kinase Src by GPCR-beta-arrestin complexes. 
  • Apparent loss-of-function mutant GPCRs revealed as constitutively desensitized receptors. 
  • Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. 
  • Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. 
  • Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. 
  • BiPS, a photocleavable, isotopically coded, fluorescent cross-linker for structural proteomics. 
  • Complex selection on a regulator of social cognition: Evidence of balancing selection, regulatory interactions and population differentiation in the prairie vole Avpr1a locus. 
  • Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. 
  • Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1. 
  • Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. 
  • Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. 
  • G Protein and β-arrestin signaling bias at the ghrelin receptor. 
  • G protein G(alpha)o is essential for vomeronasal function and aggressive behavior in mice. 
  • Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). 
  • Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. 
  • Neural correlates of mating system diversity: oxytocin and vasopressin receptor distributions in monogamous and non-monogamous Eulemur. 
  • Pain sensitivity and vasopressin analgesia are mediated by a gene-sex-environment interaction. 
  • Phosphorylation analysis of G protein-coupled receptor by mass spectrometry: identification of a phosphorylation site in V2 vasopressin receptor. 
  • Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. 
  • Regulation of V2 vasopressin receptor degradation by agonist-promoted ubiquitination. 
  • Respiration during acute hypoxia: angiotensin- and vasopressin-receptor blocks. 
  • Sexual fidelity trade-offs promote regulatory variation in the prairie vole brain. 
  • Structural studies of phosphorylation-dependent interactions between the V2R receptor and arrestin-2. 
  • Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. 
  • Structure of an endosomal signaling GPCR-G protein-β-arrestin megacomplex. 
  • The Pan social brain: An evolutionary history of neurochemical receptor genes and their potential impact on sociocognitive differences. 
  • The potential repertoire of the innate immune system in the bladder: expression of pattern recognition receptors in the rat bladder and a rat urothelial cell line (MYP3 cells). 
  • Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure? 
  • Universal nomenclature for oxytocin-vasotocin ligand and receptor families. 
  • Vasopressin receptor antagonists. 
  • Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. 
  • Vasopressin: a new target for the treatment of heart failure. 
  • Ventilatory and metabolic effects of hypercapnia in conscious rats: AVP V1 receptor block. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology